XNW1011 / SinoMab, Everest Medicines, Evopoint - LARVOL DELTA

Novel Bruton's Tyrosine Kinase Inhibitor EVER001 in Chinese Patients With Primary Membranous Nephropathy: Preliminary Results From a Phase 1b/2a Study (ERA 2025) - P1 | "Preliminary results showed that EVER001 was well tolerated and effective in patients with pMN, supporting its potential as a treatment for proteinuric autoimmune glomerular diseases."

Clinical • P1/2 data • Anemia • Glomerulonephritis • Hematological Disorders • Immunology • Infectious Disease • Renal Disease • Respiratory Diseases

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Everest Medicines (China) Co.,Ltd. | Trial completion date: Apr 2026 ➔ Sep 2026 | Trial primary completion date: Jan 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Glomerulonephritis • Renal Disease

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001 (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Everest Medicines (China) Co.,Ltd. | Not yet recruiting ➔ Recruiting | Phase classification: P1b/2 ➔ P1

Enrollment open • Phase classification • Glomerulonephritis • Renal Disease

A randomised, controlled single and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects. (PubMed, Clin Transl Sci) - "BTK receptor occupancy remained above 83% over 24 h after single administration and remained above 80% for the MAD groups for 10 days of continuous QD administration. SN1011 was well tolerated and safe after single or multiple exposures to healthy subjects, supporting further clinical development of SN1011 for treatment of autoimmune diseases."

Journal • PK/PD data • Immunology